INVESTIGATIVE REPORTS

Decreased Chymase Activity is Associated with Increased Levels of Protease Inhibitors in Mast Cells of Psoriatic Lesions

ILKKA T. HARVIMA, LEENA HAAPANEN, LEENA ACKERMANN, ANITA NAUKKARINEN, RAUNO J. HARVIMA and MAIJA HORSMANHEIMO

Departments of Dermatology and Clinical Pathology, Kuopio University Hospital, Kuopio, Finland

Mast cells contain large amounts of the powerful serine proteases, tryptase and chymase, of which only chymase can be inactivated by serum protease inhibitors. In this study, 20 patients with psoriasis and a control group of 13 with atopic dermatitis were biopsied for lesional and non-lesional skin specimens. The presence of chymase inhibitor (z1-protease inhibitor (z1-PI), z1-antichymotrypsin (z1-AC), z2-macroglobulin (z2-MG) and C1-esterase inhibitor (C1-Inh)) immunoreactivity in mast cells was verified using the sequential double-staining method. Tryptase- and chymase-positive mast cells were stained enzyme-histochemically. Tryptase-positive mast cells were increased in number in the upper dermis of the psoriatic lesion compared with lesion-free psoriatic skin (308 ± 109 vs. 100 ± 29 cells/mm2, respectively, mean ± SD, p < 0.0005, t-test) while the percentage of mast cells showing chymase activity was decreased (76.8 ± 22.1% vs. 28.6 ± 14.4%, p < 0.0005). These findings are consistent with our previous ones. In contrast to the decreased percentage of chymase-positive mast cells, a novel finding was that the percentages of C1-PI mast cells increase in number in the psoriatic lesion induced by suction blister (13.7 ± 10.0% vs. 11.0 ± 6.1%, p < 0.7). The localization of these inhibitors in mast cells is not a characteristic feature of psoriasis, since mast cells in atopic dermatitis skin also showed immunoreactivity though in slightly lower percentages. Previously, we have shown that MC TC cells contain tryptase (8, 9), chymase (10, 11), a cathepsin G-like proteinase (12) and a metalloproteinase, carboxypeptidase (13). Human mast cells can be divided into 3 subclasses based on their protease composition. MC TC cells contain tryptase exclusively, whereas MC TC cells contain tryptase, chymase, carboxypeptidase and a cathepsin G-like proteinase. MC TC cells contain chymase but not tryptase. The majority of mast cells in normal skin are MC TC cells (12 – 16).

In the psoriatic lesion, MC TC cells are predominantly responsible for the mast cell infiltration into the papillary dermis where they are frequently found in close contact with the epidermis, and occasionally in the epidermal compartment (2, 3, 15). Although chymase protein can be detected immunohistochemically in most mast cells, chymase exhibits negligible enzyme activity towards its specific enzyme-histochemical substrate, Suc-Val-Pro-Phe-4-methoxy-2-naphthylamide, in mast cells in the papillary dermis of the psoriatic lesion (3, 15). In fact, chymase activity begins to decline early in the upper dermis of the developing psoriatic lesion induced by tape-stripping. Since chymase can be inactivated by z1-protease inhibitor (z1-PI) and z1-antichymotrypsin (z1-AC) (17), a possible explanation for the inactive chymase would be the localization of these inhibitors in mast cells of both lesional and non-lesional psoriatic skin (15). In contrast to chymase, tryptase displays full enzyme activity in all mast cells of the psoriatic lesion (2). Furthermore, tryptase could have a prolonged action time following its release from mast cells since no physiological inhibitors have yet been found for tryptase (18).

Several investigators have emphasized the role of proteolytic enzymes in the pathogenesis of psoriasis. Especially, epidermal serine proteinases have received considerable attention (19 – 22), and increased levels of plasminogen activator (23, 24), kallikreins (25) and elastase (26, 27) have been detected in lesional epidermis. In addition, reduced levels of specific anti-elastase activity in suction blister fluid of non-lesional skin have been measured (28). All these findings suggest a marked alteration in proteolytic activity in psoriatic skin. Also, increased prevalence of variant phenotypes (MS, MZ and SS) of z1-PI has been reported in psoriatic patients with severe skin symptoms (29,
The staining intensity of protease inhibitors in mast cells was evaluated as weak, moderate or intense. 

**Table I. Protease inhibitors and proteinase activity in mast cells of psoriatic skin.** Tryptase-positive cells reflect the total mast cell count (MC\textsubscript{\lambda} and MC\textsubscript{\lambda\textsubscript{C}}). The staining intensity of protease inhibitors in mast cells was evaluated as weak, moderate or intense.

| Mast cell staining | Lesional skin | Non-lesional skin |
|-------------------|---------------|------------------|
|                    | Cells/mm\textsuperscript{2} | % (of total cells) | Cells/mm\textsuperscript{2} | % (of total cells) |
| Tryptase activity (n = 20) | 308 ± 109\textsuperscript{b} | 28.6 ± 14.4\textsuperscript{b} | 100 ± 29\textsuperscript{b} | 76.8 ± 22.1\textsuperscript{b} |
| Chymase activity (n = 20) | 89 ± 49 | 75 ± 28 | 50.9 ± 17.7\textsuperscript{b} | 33.4 ± 18.6\textsuperscript{b} |
| \(\alpha_1\)-Proteinase inhibitor (n = 20) | At least weak staining | 87.8 ± 9.5\textsuperscript{b} | 59.0 ± 12.5\textsuperscript{b} |
| At least moderate staining | 72.2 ± 14.9\textsuperscript{b} | 74.9 ± 12.5\textsuperscript{b} |
| \(\alpha_1\)-Antichymotrypsin (n = 20) | At least weak staining | 94.7 ± 4.0\textsuperscript{a} | 59.5 ± 12.6\textsuperscript{b} |
| At least moderate staining | 86.9 ± 7.2\textsuperscript{a} | 6.2 ± 3.5\textsuperscript{a} |
| \(\alpha_2\)-Macroglobulin (n = 10) | At least weak staining | 16.8 ± 7.0\textsuperscript{a} | 11.0 ± 6.1 |
| At least moderate staining | 13.7 ± 10.0 |

The values are expressed as mean ± SD. \(a p < 0.002; \^ b p < 0.0005\) (paired t-test, lesional vs. non-lesional skin).

Psoriatic patients with \(\alpha_1\)-PI deficiency (MZ phenotype) even show more and larger basal keratinocyte herniations through the gaps in the basal lamina than controls (31).

Since chymase and trypase are major secretory proteins in mast cell granules both with potent biological activities we have investigated and extended our preliminary observations on the localization of \(\alpha_1\)-proteinase inhibitor and \(\alpha_1\)-antichymotrypsin in mast cells (15) and now performed a quantitative analysis in a new biopsy series to show alterations in \(\alpha_1\)-proteinase inhibitor and \(\alpha_1\)-antichymotrypsin, but also, in this study, alterations in C1-esterase inhibitor and \(\alpha_2\)-macroglobulin. For this, we took skin biopsies from patients with psoriasis vulgaris and atopic dermatitis chosen as the control disease for psoriasis. No previous reports are available to show protease inhibitors in mast cells of atopic dermatitis lesions. Enzyme- and immunohistochemistry were applied to demonstrate trypase and chymase enzyme activity as well as different protease inhibitors in mast cells using a method described previously (15).

**MATERIALS AND METHODS**

**Chemicals**

The source for chemicals and materials has been reported in our previous study (15). The substrates (Z-Gly-Pro-Arg-4-methoxy-2-naphthylamide and Suc-Val-Pro-Phe-MNA) for enzyme-histochemistry were purchased from Bachem (Bubendorf, Switzerland). Rabbit antibodies against \(\alpha_1\)-protease inhibitor (\(\alpha_1\)-PI), \(\alpha_1\)-antichymotrypsin (\(\alpha_1\)-AC) and \(\alpha_2\)-macroglobulin (\(\alpha_2\)-MG) were obtained from Dako (Glostrup, Denmark), and a rabbit antibody against complement C1-esterase inhibitor (C1-Inh) from Calbiochem (La Jolla, CA, USA).

**Patients and skin and blood samples**

The study included 20 subjects with psoriasis vulgaris (11 males and 9 females, age range 23–69 years, mean age 51 years). All patients were biopsied from untreated skin sites for a psoriatic lesion and a healthy-looking skin sample (at least 2 cm away from the psoriatic plaque). Only patients without any systemic or effective local treatments for at least 1 month prior to biopsy were accepted. The clinical condition of the patients was variable from occasional to widely spread psoriatic plaques (Psoriasis Area and Severity Index, PASI, 1.6–20.5, mean 6.7).

A total of 13 patients with atopic dermatitis were selected according to the diagnostic criteria of Hanifin & Rajka (32) and they served as the control group. These patients had either acute or subacute exacerbation of the skin rash, and each of them was biopsied for lesional and non-lesional skin samples.

Skin biopsies were taken after local anaesthesia (1% lidocaine with adrenaline) in the Department of Dermatology, Kuopio University Hospital. After removal, the specimens were immediately embedded in OCT compound (Miles Scientific, Naperville, IL, USA) and frozen in isopentane cooled with a mixture of absolute ethanol and dry ice. Blood samples were drawn from antecubital veins using routine techniques. Serum \(\alpha_1\)-PI concentration was measured using immunnoassay and its isotypes with isoelectric focusing (29–31). The methods used were approved by the Ethics Committee of Kuopio University Hospital, Kuopio, Finland.

**Enzyme-histochemical staining methods for trypase and chymase**

Cryosections 4 μm thick were cut on poly-L-lysine coated slides which were stored at −20°C. Prior to staining, the sections were fixed in 0.6% formaldehyde and 0.5% acetic acid, pH 7.2, for 10 min. Mast cell trypase was stained with 1 mM Z-Gly-Pro-Arg-MNA as the selective and sensitive substrate as described previously (9, 15). Mono Mac 6 and U937 monocyctic cell lines show no staining but KU812 basophilic cell line exhibits less than 0.5% of the cells as trypase-positive (33). MOLT-4 T lymphoblasts show no staining either (unpublished). Mast cell chymase was stained with 1 mM Suc-Val-Pro-Phe-MNA as the specific substrate (3, 15).

**Immunohistochemical staining methods**

For immunohistochemical staining, the skin sections were fixed in cold acetone for 15 min. The bound polyclonal anti-\(\alpha_1\)-PI (0.55 μg/ml), anti-\(\alpha_1\)-AC (3.4 μg/ml), anti-C1-Inh (1:500), and anti-\(\alpha_2\)-MG (0.72 μg/ml) antibodies on skin sections were visualized with Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) as described previously (15). Non-specific staining was ruled out by using 100 μg/ml purified goat IgG (Sigma, St. Louis, MO, USA) dissolved in 1% bovine serum albumin and phosphate-buffered saline as the blocking reagent and by using unrelated rabbit polyclonal antibodies in higher concentrations than the specific antibodies.

**Sequential double-staining method**

The immunoreactivity of protease inhibitors in mast cells was shown with the sequential double-staining method by first demonstrating mast cell trypase with Z-Gly-Pro-Arg-MNA (15, 33). Thereafter, at least 6 adjacent photographs from the epidermal border to approximately 0.4 mm down the dermis were taken at random sites. Subsequently, the red azo dye was dissolved away by an overnight...
incubation in 15\% Tween 20. Then, the same sections were fixed in acetone, stained immunohistochemically and re-photographed at exactly the same site as the previous pictures. The control skin sections were processed identically but with unrelated rabbit antibodies. The intensity of the staining reaction product in mast cells was graded as weak staining (very faint but clearly identifiable staining product), moderate staining, and intense staining.

Counting of mast cells and statistics
Mast cells showing tryptase or chymase activity were counted, as described (15), in an area of 1.2 mm wide × 0.4 mm deep immediately beneath the papillary dermis. The area of lesional papillary dermis was measured with the Quantimet image analysis system (Leica, Nussloch, Germany), and the mast cells in papillary dermis were then counted separately (3, 15). The number and the percentage of α1-PI\textsuperscript{+}, α1-AC\textsuperscript{+}, CI-Inh\textsuperscript{+} and α2-MG\textsuperscript{+} mast cells was counted by comparing the photographs simultaneously as described previously (33). Student’s t-test was used for statistical analysis.

RESULTS
Tryptase and chymase in psoriatic skin
The density of tryptase\textsuperscript{+} and chymase\textsuperscript{+} mast cells in the upper dermis of non-lesional psoriatic skin was 100 ± 29 and 75 ± 28 cells/mm\textsuperscript{2}, respectively (Table I). Since both tryptase and chymase enzyme activities co-exist in the same mast cells, as shown previously by a sequential double-staining method (3), on an average 76.8 ± 22.1\% of the tryptase\textsuperscript{+} cells displayed chymase activity.

As shown in Table I, tryptase\textsuperscript{+} cells were significantly increased in number by 3-fold (p < 0.0005) in the psoriatic lesion compared with non-lesional psoriatic skin. In contrast, lesional skin mast cells with chymase activity exhibited only weak staining intensity in the uppermost dermis, but clear staining in the deeper part of dermis and chymase\textsuperscript{+} cell count did not differ significantly from that observed in non-lesional skin (89 ± 49 vs. 75 ± 28 cells/mm\textsuperscript{2}) (for a figure showing chyma-
Chymase activity in the psoriatic lesion see our previous study (3)). However, the percentage of chymase+ mast cells in lesional skin was significantly reduced to one third (p < 0.0005). In general, these results agree with our previous ones in 2 other series of psoriasis specimens (3, 15). The concern that chymase could be inactivated by soluble endogenous protease inhibitors during the 30-min staining reaction is not likely since inclusion of pure α1-PI or α1-AC in the staining solution could not markedly interfere with the chymase staining in non-lesional skin under experimental conditions nor could the prolonged fixation of skin sections yield any additional chymase activity in the papillary dermis of lesional skin (15).

Protease inhibitors in mast cells of psoriatic skin

The presence of various protease inhibitors in mast cells was quantified, and the results are summarized in Table I. Immunoreactivity for α1-PI, α1-AC, α2-MG and C1-inh could be

---

Fig. 3. A section of lesional psoriatic skin stained with (a) polyclonal anti-α1-proteinase inhibitor antibody. After photographing, the same section was stained with (b) Z-Gly-Pro-Arg-MNA as the substrate and Fast Garnet GBC as the chromogen. Numerous α1-proteinase inhibitor-positive cells exhibit tryptase activity (bright red stain). Magnification × 380.

---

Fig. 4. Association between mast cells showing chymase activity with those displaying (a) α1-antichymotrypsin immunoreactivity (r = −0.61, p = 0.004, Spearman correlation test), and with those displaying (b) α1-proteinase inhibitor immunoreactivity (p = 0.441 and r = −0.19, when the single deviating value is omitted) in the upper dermis of the psoriatic lesion in 20 subjects with psoriasis vulgaris. The percentages were calculated in relation to tryptase-positive mast cells.

---

Acta Derm Venereol (Stockh) 79
There were also numerous cells other than mast cells with immunoreactivity for \( \alpha_1 \)-PI and \( \alpha_1 \)-AC as found previously (15). These cells are probably macrophages that are known to be positive for these inhibitors. \( \alpha_1 \)-PI and \( \alpha_1 \)-AC exhibited high percentages even in non-lesional skin (33.4 ± 18.6% and 59.5 ± 12.6%, respectively) (Fig. 1). A relatively low proportion of the mast cells in non-lesional skin were positive for \( \alpha_2 \)-MG and CI-inh (6.2 ± 5.5% and 11.0 ± 6.1%, respectively).

The percentage of \( \alpha_1 \)-PI\(^+\), \( \alpha_1 \)-AC\(^+\) and \( \alpha_2 \)-MG\(^+\) mast cells, but not CI-inh\(^+\), was significantly increased in the psoriatic lesion compared with non-lesional controls. Furthermore, the mast cells appeared to show more intense staining for \( \alpha_1 \)-PI and \( \alpha_1 \)-AC in the psoriatic lesion (Fig. 2) since relatively higher proportion of the mast cells were at least moderately stained (Table I). As much as 86.9 ± 7.2% and 72.2 ± 14.9% of the mast cells were positive for \( \alpha_1 \)-AC and \( \alpha_1 \)-PI, respectively, but only 16.8 ± 7.0% for \( \alpha_2 \)-MG, in the psoriatic lesion. The increasing percentage of \( \alpha_1 \)-AC but not that of \( \alpha_1 \)-PI immunoreactivity in mast cells is significantly associated with a decreasing percentage of chymase activity in individual patients (Fig. 4a,b).

Two patients out of 20 showed MZ \( \alpha_1 \)-PI phenotype in serum with an \( \alpha_1 \)-PI concentration of 1.5 g/l and 1.5 g/l, but the remaining 18 patients exhibited MM phenotype with an \( \alpha_1 \)-PI concentration of 2.0 ± 0.3 g/l (mean ± SD). In addition, these MZ phenotype patients showed 95.6% and 80.2% of the lesional skin mast cells as \( \alpha_1 \)-PI positive (at least moderate staining intensity), which are slightly higher percentages than the mean (72.2%).

**Protease inhibitors in mast cells of atopic dermatitis skin**

To determine whether the expression of protease inhibitors in mast cells is characteristic for psoriatic skin, lesional and lesion-free skin specimens from patients with atopic dermatitis were double-stained as described above. Lesional atopic skin showed 55.5 ± 16.4% of the mast cells as \( \alpha_1 \)-AC positive with at least moderate staining intensity, which is significantly higher than the percentage found in non-lesional skin (40.2 ± 15.3%) (\( p < 0.03, n = 13 \)). However, no significant increases in the percentages of CI-inh\(^+\) and \( \alpha_2 \)-MG\(^+\) mast cells were observed from non-lesional to lesional skin (from 5.5 ± 7.4% to 9.7 ± 6.8%, \( p < 0.3, n = 5 \); and from 5.6 ± 7.1% to 14.3 ± 12.1%, \( p < 0.11, n = 6 \), respectively).

**DISCUSSION**

Several previous reports have shown that human cutaneous mast cells display immunoreactivity for \( \alpha_1 \)-PI and \( \alpha_1 \)-AC (15, 34–36). In fact, the cytoplasmic staining of these inhibitors in mast cells has been shown to be intense and granular in formalin-fixed and paraffin-embedded skin specimens (35, 36), supporting the assumption that mast cells have the capability to synthesize and store these substances in their secretory granules. However, serum contains high levels of \( \alpha_1 \)-PI and \( \alpha_1 \)-AC which could diffuse from circulation and bind to their counterpart proteases exposed to the extracellular environment after mast cell degranulation.

In our previous studies, we have used the double-staining method to demonstrate both tryptase enzyme activity and immunoreactivity in the same mast cells of normal, mastocytoma and psoriatic skin (2, 9, 15). In every case, tryptase protein without enzyme activity has not been observed, which is in good agreement with the findings that no known physiological inhibitors for tryptase have been found. Serum protease inhibitors do not inhibit tryptase nor can tryptase degrade them (18, 37). However, in inflamed herpes zoster skin we have observed tryptase immunoreactivity without apparent enzyme activity but the cellular origin of this tryptase protein is obscure (33). Tryptase is considered a powerful mediator with a prolonged action time since it is bound to large heparin proteoglycan complexes that diffuse slowly from the site of mast cell activation (18). Chymase, on the other hand, is susceptible to inactivation by \( \alpha_1 \)-PI and \( \alpha_1 \)-AC but it can also degrade these inhibitors efficiently (17, 38). \( \alpha_1 \)-PI can be inhibited by other enzymes, too, including neutrophil myeloperoxidase (39), cathepsin L (40), matrix metalloproteinases, such as matrilysin, gelatinase, collagenase and stromelysin (41), and *Staphylococcus aureus* serine protease (42). Tryptase could be increased by \( \alpha_1 \)-PI inactivation indirectly by activating first matrix metalloproteinases (43, 44). Also CI-Inh and \( \alpha_1 \)-AC are susceptible to inactivation by several different proteolytic enzymes (45).

In the present study, tryptase\(^+\) mast cells were significantly increased in number, but the percentage of mast cells showing chymase activity was greatly reduced in the psoriatic lesion, which is in agreement with our previous work (3, 15). We have also counted tryptase\(^+\) and chymase\(^+\) mast cells during prick-test wheal reactions in healthy-looking skin and found a deeper reduction in chymase\(^+\) cells than in tryptase\(^+\) cells only 30 min after the allergen challenge (unpublished). In contrast to chymase, the percentage of mast cells containing \( \alpha_1 \)-PI, \( \alpha_1 \)-AC and \( \alpha_2 \)-MG was significantly increased in the psoriatic lesion compared with lesion-free skin. No significant increase could be observed in CI-Inh-positive mast cells. This apparent inactivation of chymase together with simultaneous upregulation of its inhibitors in mast cells suggests that these protease inhibitors have inhibited chymase. Although chymase is inhibited relatively slowly by \( \alpha_1 \)-PI and \( \alpha_1 \)-AC compared with the inhibition rate of cathepsin G and elastase (17), chymase could be exposed to increased concentrations of \( \alpha_1 \)-PI and \( \alpha_1 \)-AC in the psoriatic lesion where mast cells are in the stage of degranulation (5, 6) and functionally hyperreactive (46). Thus, these inhibitors could take the control over released chymase at the physiological pH of extracellular environment. The previous report by Schechter et al. (17) has shown that \( \alpha_1 \)-PI and \( \alpha_1 \)-AC account for the major inhibitory capacity of plasma on human chymase, whereas only 20% of the chymase inactivation could be explained with \( \alpha_2 \)-MG. Furthermore, \( \alpha_1 \)-AC is a more potent inhibitor of chymase than \( \alpha_1 \)-PI (17). This well agrees with the present finding that \( \alpha_1 \)-AC showed highest percentages in mast cells of both lesional and non-lesional psoriatic skin (Table I), and there is a significant inverse correlation between \( \alpha_1 \)-AC and chymase-positive cells (Fig. 4). However, the expression of these protease inhibitors in mast cells is not a unique feature of psoriasis since mast cells in atopic dermatitis skin, mastocytoma skin (34–36) and herpes zoster skin (33) can also express these inhibitors.

The biological function of chymase is still obscure, though several reports have been published in this field. Chymase is supposed to modulate the cytokine cascade in psoriasis since it can efficiently activate pro-interleukin-1β to interleukin-1β (47). The increase in non-functional interleukin-1β in psoriasis (48) could, in part, be due to the inactivation of chymase. Other
possible functions of chymase are its degradative effects on neuropeptides substance P (SP) and vasoactive intestinal peptide (VIP) (49), and on bradykinin (50). SP and VIP can substantially induce degradation of skin mast cells (51). On the other hand, increased neurofilament-, SP- and VIP-positive sensory nerve fibres and their morphological contacts with mast cells have been found in the psoriatic lesion (52). The apparent inactivation of chymase by protease inhibitors observed on skin sections could result in the failure of controlling the SP-mediated neurogenic inflammation in psoriasis. This hypothesis is supported by the finding that chymase can degrade SP, whereas tryptase cannot (49, 53).

The high expression of \(\gamma_1\)-AC and \(\gamma_1\)-PI, but low expression of \(\gamma_2\)-MG and C1-Inh, in mast cells of lesional and even lesion-free psoriatic skin suggests that mast cells attempt to control their proteolytic enzymes, chymase and a cathepsin G-like proteinase, by themselves. Mast cells even exhibited those protease inhibitors which can efficiently inhibit these chymotryptic enzymes (17, 38). The other well-known target of \(\gamma_1\)-PI is neutrophil elastase in psoriatic skin (26, 27). However, whether mast cells can synthesize these inhibitors or whether they are derived from dilated capillaries remains to be examined, but it is possible that both mechanisms are working during inflammation.

In cutaneous inflammatory reactions, numerous proteases and their inhibitors are functioning simultaneously. While protease inhibitors attempt to control the destructive attack of proteolytic enzymes, these proteases try to escape by destroying their inactivators. In the psoriatic lesion, like also in herpes zoster (33) and atopic dermatitis skin (54), \(\gamma_1\)-AC and \(\gamma_1\)-PI probably have taken control over chymase. This suggests that chymase can have suppressive effects on the inflammation in psoriasis whereas tryptase can promote it.

ACKNOWLEDGEMENT

We thank Ms Anne Koivisto for her expert technical assistance.

REFERENCES

1. Toruniowa B, Jablonska S. Mast cells in the initial stages of psoriasis. Arch Dermatol Res 1988; 280: 189 – 193.
2. Harvima IT, Naukkarinen A, Harvima RJ, Horsmanheimo M. Enzyme- and immunohistochemical localization of mast cell tryptase in psoriatic skin. Arch Dermatol Res 1989; 281: 387 – 391.
3. Harvima IT, Naukkarinen A, Harvima RJ, Aalto M-L, Neitanaamaki H, Horsmanheimo M. Quantitative enzyme-histochemical analysis of tryptase- and chymase-containing mast cells in psoriatic skin. Arch Dermatol Res 1990; 282: 428 – 433.
4. Michelsson G, Krazz W, Hagforsen E, Pihl-Lundin I, Löfö L, Scheynius A. The skin and the gut in psoriasis: the number of mast cells and CD3+ lymphocytes is increased in noninvolved skin and correlated to the number of intraepithelial lymphocytes and mast cells in the duodenum. Acta Derm Venereal (Stockh) 1997; 77: 343 – 346.
5. Brody I. Mast cell degranulation in the evolution of acute erosive guttate psoriasis vulgaris. J Invest Dermatol 1984; 82: 460 – 464.
6. Brody I. Dermal and epidermal involvement in the evolution of acute erosive guttate psoriasis vulgaris. J Invest Dermatol 1984; 82: 465 – 470.
7. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 1985; 277: 352 – 358.
8. Harvima IT, Schechter NM, Harvima RJ, Fräki JE. Human skin tryptase: purification, partial characterization and comparison with human lung tryptase. Biochim Biophys Acta 1988; 957: 71 – 80.
9. Harvima IT, Naukkarinen A, Harvima RJ, Fräki JE. Immunoperoxidase and enzyme-histochemical demonstration of human skin tryptase in cutaneous mast cells in normal and mastocytoma skin. Arch Dermatol Res 1988; 280: 363 – 370.
10. Schechter NM, Fräki JE, Geessin JC, Lazarus GS. Human skin chymotryptic proteinase: isolation and relation to cathepsin G and rat mast cell protease I. J Biol Chem 1983; 258: 2973 – 2978.
11. Sayama S, Iozzo RV, Lazarus GS, Schechter NM. Human skin chymotrypsin-like proteinase chymase: subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans. J Biol Chem 1987; 262: 6808 – 6815.
12. Schechter NM, Irani A-MA, Sprows JL, Ahnert E, Wintroub B, Schwartz LB. Identification of a cathepsin G-like proteinase in the MCT and MCTC type of human mast cells. J Immunol 1990; 145: 2652 – 2661.
13. Irani A-MA, Goldstein SM, Wintroub BU, Bradford T, Schwartz LB. Human mast cell carboxypeptidase: selective localization to MCTC cells. J Immunol 1991; 147: 247 – 253.
14. Irani A-MA, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989; 37: 1509 – 1515.
15. Harvima IT, Naukkarinen A, Paukkonen K, Harvima RJ, Aalto M-L, Schwartz LB, Horsmanheimo M. Mast cell tryptase and chymase in developing and mature psoriatic lesions. Arch Dermatol Res 1993; 285: 184 – 192.
16. Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites: fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Path Res Pract 1993; 189: 156 – 162.
17. Schechter NM, Sprows JL, Schoenberger OL, Lazarus GS, Cooperman BS, Rubin H. Reaction of human skin chymotryptic-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem 1989; 264: 21308 – 21315.
18. Harvima IT, Harvima RJ, Naukkarinen A, Horsmanheimo M. Skin tryptase: features and expression in human dermatological disorders. In: Caughey GH, ed. Mast cell proteases in immunology and biology. New York: Marcel Dekker Inc., 1995: 25 – 46.
19. Fräki JE, Hopsu-Havu VK. Plasminogen activator and histone hydrolyzing proteases in psoriasis scales – possible role in increased cell division. Ann Clin Res 1976; 8: 335 – 339.
20. Dubertret L, Bertaux B, Fosse M, Touraine R. Localization of proteolytic activity in psoriatic skin. Br J Dermatol 1982: 107: 499 – 504.
21. Dubertret L, Bertaux B, Fosse M, Touraine R. Psoriasis: a defect in the regulation of epidermal proteases, as shown by serial biopsies after cantharidin application. Br J Dermatol 1984; 110: 405 – 410.
22. Ikeda S, Morioka S, Ogawa H. Influence of culturing temperature and protease inhibitors on the spontaneously occurring changes in the organ culture of psoriatic skin. J Dermatol Sci 1990; 1: 85 – 92.
23. Fräki JE, Lazarus GS, Gilgor RS, Marchase P, Singer KH. Correlation of epidermal plasminogen activator activity with disease activity in psoriasis. Br J Dermatol 1983; 108: 39 – 44.
24. Jensen PJ, Baird J, Morioka S, Lessin S, Lazarus GS. Epidermal plasminogen activator is abnormal in cutaneous lesions. J Invest Dermatol 1988; 90: 777 – 782.
25. Hibino T, Izaki S, Kimura H, Izaki M, Kon S. Partial purification of plasma and tissue kallikreins in psoriatic epidermis. J Invest Dermatol 1988; 90: 505 – 510.
26. Wiedow O, Wiese F, Streit V, Kalin C, Christophers E. Lesional elastase activity in psoriasis, contact dermatitis, and atopic dermatitis. J Invest Dermatol 1992; 99: 306 – 309.
27. Gliński W, Jarzabek-Chorzelska M, Kuliłowski M, Pierozynska-Dubowska M, Glińska-Ferenz M, Jablonska S. Basement membrane zone as a target for human neutrophil elastase in psoriasis. Arch Dermatol Res 1990; 282: 506 – 511.
28. Gliński W, Pierozynska-Dubowska M, Glińska-Ferenz M,
29. Beckman G, Beckman L, Liden S. Association between psoriasis and the \( \alpha_1 \)-antitrypsin deficiency gene. Acta Derm Venereol (Stockh) 1980; 60: 163 – 164.

30. Heng MCY, Moy RL, Lieberman J. \( \alpha_1 \)-Antitrypsin deficiency in severe psoriasis. Br J Dermatol 1985; 112: 129 – 133.

31. Heng MCY, Kloss SG. Electron microscopic features in psoriatic patients with \( \alpha_1 \)-antitrypsin deficiency. J Invest Dermatol 1986; 87: 59 – 64.

32. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) Suppl. 1980; 92: 44 – 47.

33. Hanićn JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) Suppl. 1980; 92: 44 – 47.

34. Horny H.-P, Schaumburg-Lever G, Bolz S, Geerts ML, Kaiserling E. Use of monoclonal antibody KPI for identifying normal and neoplastic human mast cells. J Clin Pathol 1990; 43: 719 – 722.

35. Akiyama M, Watanabe Y, Nishikawa T. Immunohistochemical characterization of human cutaneous mast cells in urticaria pigmentosa (cutaneous mastocytosis). Acta Pathol Jpn 1991; 41: 344 – 349.

36. Wood C, Sina B, Webster CG, Drachenberg CB, Reedy EA. Fibrous mastocytoma in a patient with generalized cutaneous mastocytosis. J Cutan Pathol 1992; 19: 128 – 133.

37. Alter SC, Kramps JA, Janoff A, Schwartz LB. Interactions of human mast cell tryptase with biological protease inhibitors. Arch Biochem Biophys 1990; 276: 26 – 31.

38. Schechter NM, Plotnick M, Selwood T, Walter M, Rubin H. Diverse effects of pH on the inhibition of human chymase by serpins. J Biol Chem 1997; 272: 24499 – 24507.

39. Matheson NR, Wong PS, Schuyler M, Travis J. Interaction of human \( \alpha_1 \)-proteinase inhibitor with neutrophil myeloperoxidase. Biochemistry 1981; 20: 331 – 336.

40. Johnson DA, Barrett AJ, Mason RW. Cathepsin L inactivates \( \alpha_1 \)-proteinase inhibitor by cleavage in the reactive site region. J Biol Chem 1986; 261: 14748 – 14751.

41. Sires UI, Murphy G, Baragi VM, Fliszar CJ, Welgus HG, Senior RM. Matrix is more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha 1-antitrypsin. Biochem Biophys Res Commun 1994; 204: 613 – 620.

42. Baran K, Gorka M, Potempa J, Porwit-Bobr Z. Chemoattractant activity of Staphylococcus aureus serine proteinase modified human plasma \( \alpha_1 \)-proteinase inhibitor. Antonie van Leeuwenhoek 1989; 56: 361 – 365.

43. Gruber BL, Marchese MJ, Suzuki K, Schwartz LB, Okada Y, Nagase H, Ramamurthy NS. Synovial procollagenase activation by human mast cell chymase: Dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84: 1657 – 1662.

44. Lohi J, Harvima I, Keski-Oja J. Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J Cell Biochem 1992; 50: 337 – 349.

45. Catanese J, Kress LF. Enzymatic inactivation of human plasma C1-inhibitor and \( \alpha_2 \)-antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase. Biochim Biophys Acta 1984; 789: 37 – 43.

46. Petersen LJ, Hansen U, Kristensen JK, Nielsen H, Skov PS, Nielsen HJ. Studies on mast cells and histamine release in psoriasis: the effect of ranitidine. Acta Derm Venereol (Stockh) 1998; 78: 190 – 193.

47. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1\( \beta \) (IL-1\( \beta \)) to an active IL-1 species by human mast cell chymase. J Exp Med 1991; 174: 821 – 825.

48. Cooper KD, Hammerberg C, Baadsgaard O, Elder JT, Chan LS, Sauer DN, Voorhees JJ, Fisher G. IL-1 activity is reduced in psoriatic skin: decreased IL-1\( \alpha \) and increased nonfunctional IL-1\( \beta \). J Immunol 1990; 144: 4593 – 4603.

49. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmocol Exp Therap 1988; 244: 133 – 137.

50. Travis J, Reilly C. The role of leukocyte cathepsin G and chymase in inflammation. In: Ogawa H, Lazarus GS, Hopsu-Havu VK, eds. The biological role of proteinases and their inhibitors in skin. Tokyo: University of Tokyo Press, 1985: 121 – 125.

51. Church MK, Lowman MA, Robinson C, Holgate ST, Benyon RC. Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol 1989; 88: 70 – 78.

52. Naukkarinen A, Järvinen A, Lakkakorpi J, Harvima IT, Harvima RJ, Horsmanheimo M. Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol 1996; 180: 200 – 205.

53. Tam EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 1990; 3: 27 – 32.

54. Järvinen A, Naukkarinen A, Harvima IT, Aalto M-L, Horsmanheimo M. Quantitative analysis of trypsinase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 1997; 136: 871 – 877.